NRXP - NASDAQ

NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc.

NRXPยทNASDAQ

$4.13

+2.1%
HealthcareBiotechnology

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$71.48M
EPS-1.3400
P/E Ratio-3.09
Earnings Date08/17/2026
NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. Fair Value Envelope

NRXP ยท NASDAQ

Our analysis suggests that NRXP has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.135, this represents a potential HIDDEN relative to our calculated worth for NRx Pharmaceuticals, Inc..

HIDDEN
Intrinsic Value
Current Price: $4.135

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$23.2M
+ Cash & Equivalents$7.8M
Firm Value-$15.4M
- Debt$631.0K
Equity Value-$16.0M
/ Shares Outstanding19,662,162B
DCF Value-$1
OVERVALUED BY 120%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$9.5M
-$6.4M
-$4.3M
-$2.9M
-$2.0M
-$1.3M
-$885.3K
-$596.1K
-$401.4K
-$270.2K
Maintenance CapEx
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
Owner Earnings
-$9.5M
-$6.4M
-$4.3M
-$2.9M
-$2.0M
-$1.3M
-$885.3K
-$596.1K
-$401.4K
-$270.2K
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$8.8M
-$5.5M
-$3.4M
-$2.1M
-$1.3M
-$828.6K
-$516.6K
-$322.0K
-$200.8K
-$125.2K
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your NRXP research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.